OR1S1 Inhibitors
OR1S1 Inhibitors interact directly or indirectly with pathways and processes that are crucial for OR1S1 function. Forskolin, while often used to increase cAMP in studies, leads to PKA activation which can phosphorylate and ultimately lead to the inhibition of OR1S1. Similarly, KT5720, as a PKA inhibitor, can impede the phosphorylation necessary for OR1S1 activation. Go 6983 and ML-7 target the kinase activity of PKC and MLCK, respectively, both of which can modulate GPCR signaling, indicating their potential to inhibit OR1S1 function through reduced phosphorylation or receptor trafficking. Loperamide and Verapamil are known to affect calcium channels, and since calcium ions can play a role in GPCR regulation, these agents can indirectly inhibit OR1S1 by impeding necessary calcium-dependent signaling events.
The cellular architecture and kinase activity play significant roles in OR1S1 functionality and are targets for several inhibitory compounds. Y-27632 and Xestospongin C influence signaling by altering cytoskeletal dynamics and calcium storage, respectively, which could disrupt the proper localization and function of OR1S1. BAPTA-AM's role as a calcium chelator further emphasizes the importance of calcium in OR1S1 signaling, as it would sequester calcium ions and prevent their signaling functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. By inhibiting these receptors, it can lead to a decrease in intracellular cAMP, which is a second messenger involved in olfactory signaling. Reduced cAMP levels would inhibit OR1S1 activity by preventing proper G protein-coupled receptor signaling. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis toxin is an inhibitor of Gi/o proteins. By inactivating these proteins, it can prevent OR1S1 from inhibiting adenylate cyclase, thus leading to an increase in cAMP which paradoxically can lead to receptor desensitization and decreased OR1S1 signaling. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may also inhibit protein phosphorylation necessary for GPCR function. Reduced phosphorylation can result in decreased OR1S1 signaling due to insufficient receptor activation or recycling. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine is an atypical antipsychotic that can indirectly reduce cAMP by antagonizing various receptors. This can lead to a decrease in OR1S1 activity since cAMP is a second messenger in its signaling pathway. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is an inhibitor of purinergic receptors that could affect ATP signaling. If OR1S1 signaling involves ATP, suramin could indirectly inhibit OR1S1 activity by disrupting purinergic receptor-mediated pathways. | ||||||
Mibefradil dihydrochloride | 116666-63-8 | sc-204083 sc-204083A | 10 mg 50 mg | $213.00 $865.00 | 4 | |
Mibefradil is a T-type calcium channel blocker. By inhibiting these channels, it can reduce calcium signaling that might be necessary for OR1S1 function, leading to decreased receptor activity. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist that can reduce cAMP levels. Decreased cAMP would inhibit OR1S1 by impairing the necessary G protein-coupled receptor signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an MEK inhibitor that can reduce the MAPK/ERK pathway activity. Since GPCRs, including OR1S1, can signal through MAPK/ERK, inhibition of this pathway can lead to reduced OR1S1 function. | ||||||